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olfactory neuroblastoma (ON), an exceedingly rare sino-nasal tumor typically treated

registry analysis, we investigated the role of chemotherapy (CT) in the treatment of
with surgery and/or radiation therapy (RT).
Methods: We analyzed all patients in the SEER registry diagnosed with a single primary malignancy of ON, a primary tumor site within the nasal cavity or surrounding
sinuses, sufficient staging information to derive Kadish staging, and >0 days of survival, ensuring follow-up data. Receipt of CT in the SEER registry was documented as
either Yes or No/Unknown.
Results: Six hundred and thirty-six patients were identified. One hundred and ninetyfive patients received CT as part of their treatment for ON. Following propensity
score matching and inverse probability of treatment weighting, there was inferior
overall survival (OS) (HR 1.7, 95% CI: 1.3-2.2, P = .001) and cancer-specific survival
(CSS) (HR 1.8, 95% CI: 1.3-2.4, P < .001) for patients who received CT compared to
those who were not treated with CT or had unknown CT status. On subgroup analysis, the only patient population that derived benefit from CT were patients who did
not receive surgery and were treated with CT and/or RT (HR 0.3, 95% CI:
0.14-0.61, P < .001).
Conclusions: Based on this retrospective SEER registry analysis, the use of CT in the
management of ON is associated with decreased OS. Our analysis suggests that
patients who are considered nonsurgical candidates may benefit from the addition of CT.
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I N T RO DU CT I O N

from the olfactory epithelium in the cribriform plate. ON represents
between 3% and 6% of all cancers in the nasal cavity and paranasal

Olfactory neuroblastoma (ON), also known as esthesioneuroblastoma,

sinuses.1,2 Since the initial description of “esthésioneuroépithéliome

is an uncommon, malignant tumor of the nasal vault believed to arise

olfactif” by Bergery and Luc in 1924, there have been approximately
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medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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1000 cases documented in the worldwide literature.2,3 The rarity of

To date, there have be no randomized controlled trials conducted

this malignancy has significantly contributed to the persistent ques-

to assess the definitive standard treatment regimen for patients with

tions regarding the cellular origin of olfactory neuroblastoma, the var-

ON. The majority of published data is from retrospective single insti-

ied biologic activity of the tumor, a staging system that correlates

tution analysis, with varied utilization and combinations of surgery,

with prognosis, and continued debate regarding the optimal standard

radiation therapy (RT), and chemotherapy (CT).15-19 Most institutions

treatment for this disease.

have adopted a combination of surgery and RT to treat ON, consis-

Despite few cases of olfactory neuroblastoma, there are several epidemiological factors that have been well-established includ-

tent with a published meta-analysis demonstrating that a bi-modality
approach achieves the highest cure rates.2

ing equal distribution between men and women and more frequent

Histological similarities between ON and other chemosensitive

presentation in Caucasian populations. Although cases have been

malignancies, such as small cell carcinoma and primitive neu-

seen in patients of all ages, some have suggested a bimodal distri-

roectodermal tumors, suggest a potential role for CT in the defini-

bution in the age of presentation, with peak incidence occurring

tive treatment of this disease. Despite the historical precedent

during the second and sixth decades of life.4,5 Locally advanced ON

regarding the utilization of CT in the treatment of ON established

often presents with seemingly innocuous symptoms, including uni-

by Mendeloff and colleagues through their experience treating a

lateral nasal obstruction, hyposmia, and epistaxis, which may be

single patient in 1957,20 in several small published retrospective

mistaken for benign conditions such as chronic rhinosinusitis or

series, CT has commonly been reserved for the treatment of

allergic polypod sinus disease. Advanced disease may present with

advanced disease,21,22 patients with recurrence, children or

exophthalmos and amaurosis depending on the location and extent

adolescents,23 or those with inoperable disease.3,24 Unfortunately,

of disease spread. The ambiguity of presenting symptoms contrib-

all of these analyses utilized different CT regimens, timing of CT

utes to the average 6-month delay between symptom onset and

(i.e., neoadjuvant vs adjuvant), and varied combinations of surgical

diagnosis,6 the 10% to 33% of patients presenting with disease

techniques and RT modalities limiting the conclusions that can be

involving the cervical lymph nodes at the time of diagnosis, and the

drawn from this data.

12% to 25% of patients who have distant metastasis of their dis-

In the setting of several inconclusive single institution analyses

ease, most commonly involving the lung, brain, and bone.4,5,7-9

utilizing varied treatment regimens and limited by small sample size,

Based on a meta-analysis of available single institution trials from

we utilized the SEER national cancer registry to provide a large retro-

1990 to 2000, the mean 5-year overall survival (OS) for ON was

spective analysis exploring the role of CT in the treatment of ON.

45%, with some series publishing survival results as low as 0% and
as high as 86%, and mean disease specific survival (DSS) of 41% at
5 years.2

2

METHODS

|

While several staging systems have been proposed,6,10 an accurate
staging system for ON that correlates with disease prognosis has been

2.1

|

Data source

difficult to validate due to the infrequent occurrence of the disease.
Kadish et al.11 proposed the original staging system in 1976, based on

The SEER registry from the National Cancer Institute curates and pub-

the extent of disease infiltration into the nasal cavity and the surrounding

lishes cancer survival and incidence data obtained from population-

paranasal sinuses, which continues to be the most widely utilized staging

based cancer registries. Moreover, a specialized Radiation/Chemo-

system today. This system included three stages with stage A rep-

therapy Database (SEER 18 Custom Data, November 2017 Submis-

resenting disease limited to the nasal cavity, stage B representing malig-

sion) was used for this analysis as it contains details on RT and

nancy involving both the nasal cavity and paranasal sinuses, and stage C

CT. The SEER database has been utilized to study survival outcomes

representing disease extending beyond the nasal cavity and paranasal

of various malignancies and has proven particularly useful in the

sinuses. In an effort to better differentiate patients with local disease

assessment of uncommon diseases as it covers approximately 28% of

extension and those with distant disease, this system was modified to

the United States population from a variety of the geographic areas.25

include the addition of stage D, which represents tumors with regional

Due to the lack of any identifying information in the data collected by

12

or distant metastasis.

A surveillance, epidemiology, and end results

(SEER) analysis of the correlation between prognosis and Kadish staging

SEER, this study was exempt from Institutional Review Board
approval.

in patients with ON found the staging system to be predictive of survival,
while an analysis of the National Cancer Database (NCDB) demonstrated
no correlation between Kadish staging and survival, with improved sur-

2.2

|

Cohort analyzed

vival in Kadish stage B patients compared to stage A patients.1,13 The
Hyams staging system is an additional staging system that has been uti-

The SEER 18 Custom Data registries were queried for the Interna-

lized based on histologic factors and has been shown on retrospective

tional Classification of Disease for Oncology (ICD-0-3) histology code

14

analysis to correlate with all-cause mortality and patient outcomes.

9522/3, corresponding to ON, to identify appropriate patients diag-

The incongruity of these retrospective studies demonstrates the persis-

nosed with a single primary malignancy between 1977 and 2016. All

tent need for an accurate staging system for these patients.

included patients in this analysis had a primary tumor site within the
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nasal cavity or surrounding sinuses, had sufficient staging information

heterogeneity using a fixed effects model. Moreover, quantification of

to derive Kadish staging, and >0 days of survival ensuring follow-up

heterogeneity was assessed with the τ2 and I2 statistic.

data. Six hundred and thirty-six patients were identified in the SEER
registry that met inclusion criteria for this analysis.

All statistical analyses were completed using SEER*Stat (v8.3.5,
The Surveillance Research Program of the Division of Cancer

Kadish and Hyams staging were not coded variables in the SEER

Control and Population Sciences, National Cancer Institute), and

database; however, sufficient information, including primary disease

RStudio (v1.2.1335). The following R packages were used:

site, tumor grade, laterality of malignancy, extent of disease, and

tableone, survival, survminer, dplyr, gtsummary, gt, IPWsurvival,

lymph node involvement, was available for the majority of patients to

ipw, meta, and ggplot2. R markdown for all analyses are available

derive these values. In order to derive Hyams grading, we utilized the

upon request.

tumor grade that is recorded in the SEER database. Disease classified as
Hyams low grade consisted of tumors reported as well-differentiated
(grade I) and those reported as moderately differentiated (grade II).

3
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Hyams high grade included tumors defined as poorly (grade III) or
undifferentiated and those defined as anaplastic (grade IV). Due to the

Six hundred and thirty-six patients were identified in the SEER regis-

inherent subjectivity in the retrospective derivation of both Kadish and

try from 1977 through 2016 that met inclusion criteria for this analy-

Hyams grading, an interrater analysis was conducted between multiple

sis. The average patient age at the time of diagnosis was 51.4 years

clinicians. Each clinician independently reviewed data from the SEER reg-

(range: 0-91 years) with the majority being male (n = 380, 59.7%), and

istry and kappa statistics were completed to assess the interrater reliabil-

Caucasian (n = 512, 80.5%). The highest incidence of disease onset

ity. The kappa statistic was calculated to be 0.75 which represents

occurred in patients between the ages of 18-39 years at diagnosis

substantial agreement between the reviewers. Kadish staging was

(n = 111, 17.5%) and 40-59 years at diagnosis (n = 293, 46.1%) and

derived on 202 patients (31.8%), while 349 patients (54.9%) had suffi-

the majority of patients were diagnosed with a primary tumor involv-

cient information to derive Hymans staging.

ing the nasal cavity (n = 498, 78.3%). One hundred and ninety-five

For each patient, information regarding surgery, RT, and CT

patients (30.7%) received CT as part of their treatment for olfactory

was collected as well as relevant available information regarding

neuroblastoma. There was no statistically significant difference

the timing of therapeutic intervention in relation to other modali-

between patients that received CT as part of their treatment regimen

ties of therapy. Receipt of CT was documented in the SEER registry

and those who did not receive CT in regard to primary tumor location

as either “Yes” or “No/Unknown.” One hundred and ninety-five

(P = .8), laterality of primary tumor (P = .8), sex (P = .6), and race

patients received CT as part of their treatment for ON. OS was ana-

(P = .5). There was a significant difference between the two groups in

lyzed using patient status, reported as “Alive” or “Dead,” as well as

regard to age at diagnosis (P < .001), derived Hyams grade (P < .001),

cause of death classification reported in the SEER database for

derived Kadish stage (P < .001), treatment modality (P < .001), and

cancer-specific survival (CSS). Death due to ON was defined as any

time of follow up (P < .001). Following PS-matching and IPTW, base-

deaths that were coded as being attributable to the diagnosis of

line characteristics, including age, race, sex, primary tumor location,

ON as reported in the SEER registry.

and treatment modality, between the two patient cohorts were not
statistically different. Additional unadjusted and propensity score matched descriptive statistics for this patient cohort are available in

2.3
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Statistical analysis

Table 1. The various treatment regimens utilized in this patient cohort
are outlined in Figure 1.

Patient characteristics were evaluated pre- and postmatching with χ 2

The results of the UVA and MVA for OS are shown in Tables 2

analysis and standard mean difference (SMD), using a cut off of

and 3. Following PS-matching and IPTW, age 60-79 years at the time

SMD > 0.1 considered unbalanced.26 Univariate analysis (UVA) of patient

of diagnosis (HR 3.64, 95% CI: 1.62-8.16, P = .002), age > 80 years at

characteristics impact on OS was performed using the Kaplan-Meier

time of diagnosis (HR 14, 95% CI: 5.69-34.3, P < .001), high Hyams

(KM) method, with the log rank method (Mantel-Cox) to assess for signif-

grade (HR 2.83, 95% CI: 1.97-4.07, P < .001), derived Kadish stage C

icance. Multivariable analysis (MVA) of patient characteristics and OS

(HR 2.69, 95% CI: 1.58-4.60, P < .001) or D (HR 14.6, 95% CI:

was performed utilizing Cox proportional hazards regression modeling.

7.73-27.4, P < .001), patients who had RT and CT without surgery

Covariates included in the MVA model were selected via backward elimi-

(HR 4.66, 95% CI: 3.15-6.89, P < .001), and patients who received CT

nation, excluding covariates with P > .1. All statistical analyses are two-

(HR 1.69, 95% CI: 1.31-2.19, P < .001) were associated with

sided and statistical significance was accepted at P < .05.

decreased OS on UVA.

In order to mitigate indication bias, a propensity score (PS)-

On doubly robust IPTW-MVA, age > 60 years at the time of diag-

matched analysis with inverse probability of treatment weighting

nosis (HR 3.43, 95% CI: 1.38-8.50, P = .008), age > 80 years at time of

(IPTW) was performed.27 First, binary logistic regression modeling

diagnosis (HR 3.71, 95% CI: 1.20-11.5, P = .023), distant disease at

was used to generate PS for receipt of CT. Next, IPTW was calculated

the time of diagnosis (HR 3.93, 95% CI: 2.24-6.91), P < .001), high

as 1/PS and 1/(1 − PS).28 Finally, IPTW-UVA and doubly robust

Hyams grade (HR 1.79, 95% CI: 1.19-2.69, P = .005), derived Kadish

IPTW-MVA was performed.29 Subgroup analyses were evaluated for

stage D (HR 2.45, 95% CI: 1.00-6.00, P = .05), and utilization of CT in

&C?JRFѥ1AGCLACѥ0CNMPRQ
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Unadjusted and propensity score matched patient characteristics
Unadjusted

Age at diagnosis

Propensity score matched

Received
chemotherapy
(n = 195)

No/unknown
chemotherapy
(n = 441)

49 years

53 years

Race
Caucasian

P-value

Received
chemotherapy
(n = 183.7)

No/unknown
chemotherapy
(n = 437.5)

P-value

<.001

52 years

52.96 years

.476

.5

.428

156 (80%)

356 (81%)

136.8 (74.5%)

352.6 (80.6%)

African American

21 (11%)

36 (8.2%)

19.4 (10.6%)

38.7 (8.8%)

Other

18 (9.2%)

49 (11%)

27.4 (14.9%)

46.2 (10.6%)

Sex
Male

.6

.917

120 (62%)

260 (59%)

109.6 (59.7%)

263.6 (60.3%)

75 (38%)

181 (41%)

74.1 (40.3%)

173.9 (39.7%)

150 (77%)

348 (79%)

135.1 (73.6%)

340.9 (77.9%)

Ethmoid sinus

24 (12%)

47 (11%)

22.8 (12.4%)

44.7 (10.2%)

Other sinus

21 (11%)

46 (10%)

25.7 (14.0%)

51.9 (11.9%)

183 (94%)

419 (95%)

172.1 (93.7%)

409.3 (93.5%)

Bilateral

9 (4.6%)

15 (3.4%)

7.6 (4.1%)

21.9 (5.0%)

Unknown

3 (1.5%)

7 (1.6%)

3.9 (2.1%)

6.3 (1.4%)

34 (17%)

139 (32%)

43.3 (23.6%)

116.6 (26.6%)

Female
Primary tumor location
Nasal cavity

.8

Laterality
Unilateral

.8

Derived Hyams grade
Low

.693

.866

<.001

.822

High

80 (41%)

81 (18%)

49.7 (27.1%)

113.6 (26.0%)

Unknown

81 (42%)

221 (50%)

90.7 (49.4%)

207.3 (47.4%)

A

4 (2.1%)

36 (8.2%)

10.0 (5.4%)

27.4 (6.3%)

B

10 (5.1%)

20 (4.5%)

11.3 (6.2%)

22 (5.0%)

C

33 (17%)

69 (16%)

36.5 (19.9%)

69.2 (15.8%)

Derived Kadish stage

D
Unknown

<.001

11 (5.6%)

5 (1.1%)

137 (70%)

311 (71%)

15 (7.7%)

147 (33%)

Treatment modality
Surgery alone
Radiation alone
Surgery + radiation
Follow up (months)

.901

8.1 (4.4%)

19.8 (4.5%)

117.8 (64.1%)

299.1 (68.4%)

33.2 (18.0%)

112.4 (25.7%)

<.001

43 (22%)

12 (2.7%)

137 (70%)

282 (64%)

35

73

.352

17.3 (9.4%)

41.0 (9.4%)

133.2 (72.5%)

284.0 (64.9%)

<.001

treatment (HR 1.76, 95% CI: 1.34-2.31, P < .001) were associated with

Kaplan-Meier analysis for unadjusted and IPTW-adjusted OS and

decreased OS. In contrast, doubly robust IPTW-MVA identified female

CSS are shown in Figures 3 and 4, respectively. There was inferior OS

sex (HR 0.65, 95% CI: 0.49-0.87, P = .004) and the utilization of surgery

(HR 1.7, 95% CI: 1.3-2.2, P = .001) and CSS (HR 1.8, 95% CI: 1.3-2.4,

and RT in the treatment of olfactory neuroblastoma (HR 0.67, 95% CI:

P < .001) for patients who received CT in both the unadjusted and

0.47-0.94, P = .022) to be associated with improved OS.

IPTW-adjusted analysis compared to patients who were either not

On subgroup analysis, comparing patients who received CT and

treated with CT or had unknown CT status for their disease.

those that did not receive CT in the treatment of ON, the only patient
population that derived benefit from CT were patients who did not
receive surgery and were treated with a combination of CT and RT

4
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(HR 0.3, 95% CI: 0.14-0.61, P < .001). Patients who received treatment with surgery or a combination of surgery and RT did not benefit

Olfactory neuroblastoma is a rare malignant tumor of the nasal vault.

from the addition of CT (Figure 2).

Our patient cohort demonstrated similar characteristics to what has

&C?JRFѥ1AGCLACѥ0CNMPRQ

BRISSON ET AL.

5 of 12

F I G U R E 1 CONSORT diagram
demonstrating different treatment
regimens utilized

previously been reported in the literature, with the majority of

In contrast, there have been reports with discouraging results uti-

patients being male, Caucasian, presenting with a primary tumor of

lizing CT to treat ON. McElroy and colleagues at the Mayo Clinic pub-

the nasal cavity in the fifth decade of life.1 Although we found that

lished their 20-year experience treating ON, in which eight patients

the utilization of CT was associated with decreased OS in the treat-

were treated with platinum-based CT, but only two patients demon-

ment of ON, we importantly identified a subset of nonsurgical

strated a response to therapy. Both patients who responded had

patients who may benefit from the addition of CT to their treatment

high-grade tumors that, per the study authors, were felt to be more

regimen.

sensitive to CT.33 Despite an initial response rate of 25%, both
other

patients had decreased OS compared to patients who did not receive

chemosensitive tumors, there has been significant interest in

With

histologic

similarities

between

ON

and

CT, suggesting that despite a tumor that may be chemosensitive,

utilizing CT to improve outcomes in the treatment of this disease

cytotoxic agents do not appear to cure the malignancy.

and potentially decrease locoregional and distant failures; however,

In one of the most comprehensive reports regarding the treat-

a consensus opinion on the benefits of utilizing cytotoxic agents

ment of ON, Dulguerov and colleagues published a meta-analysis

does not exist. At most institutions, CT, commonly consisting of

which showed decreased five-year survival in patients treated with

platinum-based regimens in combination with cyclophosphamide,

surgery, RT, and CT (47%) compared to those treated with

vincristine, and occasionally doxorubicin, have been utilized in com-

chemoradiation (51%) and with surgery and RT (65%).2 Our findings

bination with surgery and/or RT and is typically reserved for treat-

of decreased OS and CSS for patients who receive CT are consistent

ment of advanced disease (i.e., Kadish stage B, C, or D),21,22

with these previously published findings. These results not only hel-

patients with recurrence,30 young patients,23 or those deemed to

ped establish surgery and RT as the widely considered standard treat-

be inoperable in an attempt to convert them to surgical candidates

ment for ON but also added additional evidence of the potential

by reducing tumor burden.

3,19,24

negative effects of utilizing CT to treat these patients.

Several institutions have published successful results with preop-

Additional data from a retrospective analysis of the SEER registry

erative CT followed by definitive treatment with surgery and

was recently published that did not support the utilization of CT in

RT.15,23,31,32 For example, the University of Virginia utilizes preopera-

the treatment of ON, showing decreased DSS or OS for patients who

tive CT followed by radiotherapy and craniofacial resection as part of

received CT.34 There are several key differences between this

32

a multimodality treatment protocol for treating ON.

This approach

recently published report and the data presented in this analysis. In

has demonstrated objective success with a 5- and 15-year disease

this report, we limited inclusion to patients who had >0 days survival

free survival of 86.5% and 82.6%, respectively. Although these results

ensuring patients would have follow up data. This likely contributed

are impressive, there have been similar results obtained without the

to the differences in the number of patients included in the two ana-

utilization of CT, making it challenging to interpret the potential bene-

lyses. Cranmer et al. utilized multiple imputation by chained equation

fit derived from the addition of CT specifically.

to account for missing data within the SEER registry; however, in this

&C?JRFѥ1AGCLACѥ0CNMPRQ
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Unadjusted and propensity score matched univariate regression analysis for overall survival
Unadjusted univariate analysis

Inverse probability of treatment weighting univariate analysis

HR

95% CI

P-value

HR

95% CI

P-value

<18

-

-

-

-

-

-

18-39

0.74

0.37-1.47

.4

1.34

0.57-3.13

.5

40-59

0.92

0.49-1.71

.8

1.45

0.64-3.25

.4

60-79

1.8

0.96-3.37

.067

3.64

1.62-8.16

.002

≥80

5.84

2.65-12.8

<.001

14

5.69-34.3

<.001

Caucasian

-

-

-

-

-

-

African American

2.32

1.61-3.35

<.001

1.98

1.39-2.82

<.001

Other

0.82

0.53-1.28

.4

0.88

0.59-1.30

.5

Male

-

-

-

-

-

-

Female

0.68

0.52-0.89

.005

0.63

0.49-0.83

<.001

Localized disease

-

-

-

-

-

-

Regional involvement

1.88

1.26-2.80

.002

1.98

1.32-2.97

.001

Distant disease

4.9

3.28-7.34

<.001

5.36

3.56-8.07

<.001

Unknown

1.45

0.73-2.86

.3

2.05

1.11-3.81

.023

Low

-

-

-

-

-

-

High

2.41

1.67-3.46

<.001

2.83

1.97-4.07

<.001

Unknown

1.28

0.91-1.80

.2

1.3

0.92-1.85

.14

A

-

-

-

-

-

-

B

1.62

0.83-3.14

.2

1.7

0.89-3.26

.11

C

2.45

1.45-4.16

<.001

2.69

1.58-4.60

<.001

D

11

5.45-22.4

<.001

14.6

7.73-27.4

<.001

Unknown

1.35

0.80-2.27

.3

1.44

0.85-2.45

.2

Covariate
Age

Race

Sex

Extent of disease

Derived Hyams grade

Derived Kadish stage

Treatment modality
Surgery alone

-

-

-

-

-

-

Radiation alone

2.99

1.97-4.54

<.001

4.66

3.15-6.89

<.001

Surgery + radiation

0.99

0.73-1.36

.9

0.85

0.62-1.16

.3

No/unknown

-

-

-

-

-

-

Yes

2.23

1.72-2.90

<.001

1.69

1.31-2.19

<.001

Chemotherapy

analysis, no derivation of previously unreported data was completed.

find that a subset of patients, those treated with chemoradiation,

The conclusions of Cranmer et al. were that the utilization of CT was

derived benefit from the use of CT.

associated with decreased DSS and OS on univariate and multivariate

The wide variability in success utilizing CT in the treatment of ON

analysis. This led the authors to conclude that there was no support

may be attributed to several clinical factors. CT has most commonly

for the utilization of CT to improve DSS or OS in the treatment of pri-

been utilized in two extreme clinical presentations: in children and

mary ON. Although our analysis supports the findings of inferior OS

adolescents and in individuals who are deemed to be poor surgical

and CSS for patients who received CT in both unadjusted and IPTW-

candidates. In young patients, aggressive therapy is more likely to be

adjusted analysis compared with patients who were either not treated

utilized due to the belief that a tri-modality approach will be better

with CT or had unknown CT status for their disease, critically, we did

tolerated and may provide increased efficacy. This has been
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Unadjusted and propensity score matched multivariate regression analysis for overall survival
Unadjusted multivariate analysis

Inverse probability of treatment weighting multivariate analysis

HR

95% CI

P-value

HR

95% CI

P-value

<18

-

-

-

-

-

-

18-39

0.83

0.40-1.74

.6

1.14

0.46-2.79

.8

40-59

1.04

0.51-2.13

.9

1.24

0.51-3.03

.6

60-79

2.61

1.23-5.53

.013

3.43

1.38-8.50

.008

≥80

3.82

1.44-10.2

.007

3.71

1.20-11.5

.023

-

-

-

-

-

-

Covariate
Age

Race
Caucasian
African American

1.9

1.28-2.82

.002

1.28

0.86-1.89

.2

Other

0.77

0.49-1.22

.3

0.93

0.61-1.41

.7

Sex
Male

-

-

-

-

-

-

Female

0.71

0.54-0.95

.021

0.65

0.49-0.87

.004

Localized disease

-

-

-

-

-

-

Regional involvement

1.63

0.96-2.78

.073

1.53

0.92-2.56

.1

Distant disease

4.06

2.28-7.21

<.001

3.93

2.24-6.91

<.001

Unknown

1.48

0.66-3.29

.3

1.8

0.85-3.81

.13

-

-

-

-

-

-

Extent of disease

Derived Hyams grade
Low
High

1.42

0.95-2.12

.09

1.79

1.19-2.69

.005

Unknown

1.1

0.76-1.58

.6

1.21

0.83-1.75

.3

A

-

-

-

-

-

-

B

1.22

0.57-2.61

.6

1.54

0.75-3.20

.2

C

1.16

0.56-2.40

.7

1.57

0.78-3.18

.2

Derived Kadish stage

D

2.58

1.03-6.48

.043

2.45

1.00-6.00

.05

Unknown

0.83

0.40-1.70

.6

0.91

0.45-1.85

.8

Surgery alone

-

-

-

-

-

-

Radiation alone

1.18

0.73-1.90

.5

1.91

1.24-2.93

.003

Surgery + radiation

0.71

0.5-1.0

.049

0.67

0.47-0.94

.022

No/unknown

-

-

-

-

-

-

Yes

1.77

1.30-2.42

<.001

1.76

1.34-2.31

<.001

Treatment modality

Chemotherapy

demonstrated in the literature with limited reported toxicity.15,23 CT

results from our subgroup analysis that suggest that the only group of

is also utilized in patients who are deemed to not be surgical candi-

patients who benefited from CT were those who were treated with

dates, potentially due to advanced disease and increased tumor bur-

chemoradiation without surgery.

den at the time of diagnosis or poor performance status. This likely

Due to the limitations of all SEER registry analyses, there are

contributes to a selection bias, where individuals with more advanced

inherent weaknesses to our patient cohort that must be acknowl-

disease are treated with tri-modality therapy or with other combina-

edged. First, the treatment data available in SEER is limited in detail

tions of therapy in an effort to decrease tumor burden. This may

and, in some cases, incomplete. Given the rarity of ON, this limitation

account for the worse outcomes in this patient population when com-

was accepted by the authors of this analysis in order to compile a

pared to the adopted standard of surgery and RT. This is supported by

large sample population of approximately 40 years of patient cases to

8 of 12
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F I G U R E 2 IPTW adjusted hazard
ratio for the benefit of chemotherapy
with various patient characteristics

assess the benefit of patients receiving CT. No derivation of missing

dose of systemic therapy, are not captured in the SEER registry and

data was performed in this patient cohort. An unintended although

limits the authors' ability to draw conclusions regarding specific treat-

necessary consequence of assessing rare malignancies treated over

ment paradigms. Additionally, the SEER registry does not provide

several decades is the large heterogeneity in treatment regimens pre-

enough information to differentiate No vs Unknown CT receipt and

sent in this patient cohort. The specific details of a patient's treatment

significantly limits detailed conclusions that can be derived from this

regimen, including specific systemic therapy, duration of treatment, or

SEER registry analysis.

BRISSON ET AL.
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The current SEER registry does not capture Kadish staging and

data in the SEER registry and assign Kadish staging and Hyams grading

Hyams grading. As a result, we utilized a previously published approach

to patients in our cohort. These reviewers had high interrater congruity

to derive these values based on available information including extent of

demonstrating substantial agreement between the reviewers. This

disease, primary tumor location, SEER historic staging information, and

decreases the inherent subjectivity of retrospective assignment of stag-

tumor grade.35 We also had independent clinicians review the available

ing information not capture in the SEER registry.

F I G U R E 3 (A) Unadjusted and (B) IPTW adjusted Kaplan-Meier curves for overall survival in patients who received chemotherapy and those
who did not receive chemotherapy or had their chemotherapy status unknown

10 of 12
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F I G U R E 4 (A) Unadjusted and (B) IPTW adjusted Kaplan-Meier curves for cancer-specific survival in patients who received chemotherapy
and those who did not receive chemotherapy or had their chemotherapy status unknown

Finally, there have been substantial questions raised regarding

literature in the last 96 years, the SEER registry offers unparalleled

the accuracy of information in the SEER registry regarding CT and

access to a large cohort of patients unmatched in any single institution

RT. In a study of several primary disease sites including prostate, lung,

analysis, providing an ideal database to conduct this analysis in which

breast, and colon cancer it was suggested that the error rate in these

a large cohort size is necessary. Despite this, the conclusions of this

data points approaches approximately 10%.36 Given the rarity of ON,

analysis should be analyzed with the knowledge of a previously publi-

with approximately 1000 documented cases in the worldwide

shed 10% error rate in these critical data fields.

&C?JRFѥ1AGCLACѥ0CNMPRQ
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C O N CL U S I O N

Despite several small single institution analyses demonstrating various
utilizations of pharmacotherapy, sequential timing of treatment
modalities, and different combinations of CT, surgery, and RT, all with
varied success, there remains significant debate regarding the role of
CT in the treatment of ON. Due to the challenges of studying a rare
disease such as ON, most notably small sample sizes, we utilized the
SEER registry to compile one of the largest published sample population to date assessing what, if any, role cytotoxic therapy should play
in the treatment of these patients. The results of this four-decade retrospective analysis indicated that the utilization of CT is associated
with decreased OS and decreased CSS consistent with a recently published analysis by Cranmer et al. However, our analysis demonstrated
a subset of patients, treated with CT and RT without surgery, who did
benefit from the utilization of CT in their treatment regimen representing a critical new finding of a patient population where further
investigation of the utilization of CT in the treatment of ON should be
considered.
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